The short answer
FIB-4 uses age, AST, ALT, and platelet count to estimate the likelihood of advanced liver scarring in an appropriate clinical context. The Healthcare Business Today article emphasizes that a result should lead to a clear clinical conversation, not a self-diagnosis.
Healthcare Business Today recently published a sponsored article about a problem many men recognize: a lab report can show numbers without explaining what to ask next. The article points readers to Aldrick’s FIB-4 guide as a resource for understanding a liver-fibrosis risk score. Here is an original look at the central ideas, with context to help you discuss them with a clinician.
Key takeaways
- Healthcare Business Today published sponsored coverage that links to Aldrick’s FIB-4 guide.
- FIB-4 is a first-pass risk assessment, not a diagnosis of liver disease.
- A clinician can put the score in context and explain whether any follow-up is appropriate.
- Age alone does not mean every man over 40 needs liver screening.
What the featured article is about
The piece follows a familiar situation: someone opens a lab report, checks for values flagged as abnormal, and still does not know whether there is a useful next step. It uses liver health to show why explaining the purpose and limits of a risk score matters as much as displaying the number.
Healthcare Business Today links to Aldrick’s FIB-4 educational guide. The full feature is available at the publication’s site using the link above; this post summarizes its themes in our own words rather than republishing it.
A score starts a conversation; it does not end one
FIB-4 combines four inputs: your age, AST, ALT, and platelet count. In people for whom a clinician considers the score appropriate, it helps sort who may need further assessment for advanced liver fibrosis. Fibrosis means scarring. A FIB-4 value does not confirm cirrhosis or directly measure scar tissue.
The feature also makes an important distinction: turning 40 alone is not a reason for everyone to seek liver screening. A clinician considers the result alongside medical history, metabolic risk factors, other possible causes of abnormal liver tests, and the timing of the blood work. Because age is part of the calculation, cutoffs are not interchangeable across all ages.
What a useful follow-up looks like
The article asks healthcare teams to make three things clear: why the score was considered, what happens next, and who is responsible for follow-up. Depending on the clinical picture, a clinician may recommend additional assessment such as liver elastography or an Enhanced Liver Fibrosis blood test. In other circumstances, reassessment later may be appropriate.
A number without a plan can be confusing. If a score has been discussed with you, ask what it means in your situation and whether another test or appointment is needed. Do not treat an online calculator as a diagnosis or assume normal-looking liver enzymes rule out every liver problem.
Where to read more
Read the original Healthcare Business Today feature for its discussion of patient communication and follow-up. For a closer look at the four inputs, how the score is used, and its limitations, read Aldrick’s related FIB-4 guide linked below. Both are educational resources, not substitutes for individual medical advice.
Questions to raise with a healthcare professional
- Given my history and risk factors, is a FIB-4 assessment appropriate for me?
- What do my underlying AST, ALT, and platelet results mean in context?
- If further evaluation is recommended, which test or appointment comes next, and who will arrange it?
When to seek care
Worth a routine appointment
- If you have been told you have fatty liver or have questions about your liver tests, discuss whether further evaluation is appropriate with your clinician.
Seek help without delay
- Seek prompt medical care for new yellowing of the skin or eyes, confusion, or a rapidly swollen abdomen rather than relying on a risk score.
References
- Healthcare Business Today. Helping Men Over 40 Understand FIB-4 and Liver Fibrosis Risk (sponsored coverage)
- American Association for the Study of Liver Diseases. Spare Me the Jab: Noninvasive Assessment in Patients with MASLD
- National Institute of Diabetes and Digestive and Kidney Diseases. Diagnosis of NAFLD & NASH
How this article is reviewed
Aldrick articles are written from published guidance and peer-reviewed research, checked against our evidence standards and re-reviewed when guidance changes. Spotted something inaccurate or out of date? Tell us and we will correct it and update the review date.
This article is educational. It does not diagnose conditions or replace evaluation by a qualified clinician.